Literature DB >> 11352438

Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers.

J Lettieri1, R Vargas, V Agarwal, P Liu.   

Abstract

OBJECTIVE: To investigate the effects of concomitant food intake on the pharmacokinetics of a single oral dose of moxifloxacin 400mg.
DESIGN: This was a randomised 2-way nonblinded crossover study in healthy volunteers. PARTICIPANTS: 18 young, healthy, male volunteers were enrolled in the study, of whom 16 were considered evaluable for the pharmacokinetic analysis.
METHODS: Moxifloxacin was given under 2 conditions separated by a 1-week washout period: fasted and fed (immediately after a standardised high fat breakfast). Concentrations of moxifloxacin in serum were determined by a validated high performance liquid chromatography procedure with fluorescence detection. OUTCOME MEASURES: Pharmacokinetic parameters such as maximum concentration (Cmax), time to reach Cmax (tmax), area under the concentration-time curve from zero to 48 hours (AUC48h), AUC from zero extrapolated to infinity (AUCinfinity) and elimination half-life (t1/2z) were estimated using noncompartmental methods. The natural logarithms of AUC and Cmax were analysed using analysis of variance. Bioequivalence of the 2 treatments was determined at the 5% significance level with the two 1-sided tests procedure and limits of 80% and 125% for AUC and 70 to 143% for Cmax.
RESULTS: The mean serum concentration versus time profiles were similar between the 2 treatments. The geometric mean AUCinfinity values under fed and fasted conditions were almost identical, 37.7 versus 38.5 mg/L x h, respectively [90% confidence interval (CI) of the ratio of fed versus fasted based on geometric least-square means was 0.95, 1.00]. Geometric mean Cmax values were slightly reduced by food, 2.5 versus 2.8 mg/L, respectively (90% CI of fed versus fasted based on geometric least-square means was 0.78, 0.98). The absorption of moxifloxacin seems to be mildly delayed because of the effect of food; the median tmax values were 1.0 and 2.5 hours for fasted and fed conditions, respectively. The single oral dose of moxifloxacin 400mg was well tolerated when taken with and without food.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11352438     DOI: 10.2165/00003088-200140001-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  15 in total

1.  The in-vitro activity of moxifloxacin against Legionella species and the effects of medium on susceptibility test results.

Authors:  G Ruckdeschel; A Dalhoff
Journal:  J Antimicrob Chemother       Date:  1999-05       Impact factor: 5.790

2.  Oral bioavailability of trovafloxacin with and without food in healthy volunteers.

Authors:  R Teng; L C Dogolo; S A Willavize; H L Friedman; J Vincent
Journal:  J Antimicrob Chemother       Date:  1997-06       Impact factor: 5.790

3.  The effect of food or milk on the absorption kinetics of ofloxacin.

Authors:  M N Dudley; C R Marchbanks; S C Flor; B Beals
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.

Authors:  P M Roblin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

5.  In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas.

Authors:  C M Bébéar; H Renaudin; A Boudjadja; C Bébéar
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

6.  Ciprofloxacin pharmacokinetics after a standard or high-fat/high-calcium breakfast.

Authors:  R W Frost; J D Carlson; A J Dietz; A Heyd; J T Lettieri
Journal:  J Clin Pharmacol       Date:  1989-10       Impact factor: 3.126

7.  Effect of food on enoxacin absorption.

Authors:  A A Somogyi; F Bochner; J A Keal; P E Rolan; M Smith
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

Review 8.  The influence of food on the absorption of antimicrobial agents.

Authors:  P G Welling; F L Tse
Journal:  J Antimicrob Chemother       Date:  1982-01       Impact factor: 5.790

9.  In vitro activity of BAY 12-8039, a new fluoroquinolone.

Authors:  J M Woodcock; J M Andrews; F J Boswell; N P Brenwald; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

Review 10.  Drug-drug interactions with ciprofloxacin and other fluoroquinolones.

Authors:  R E Polk
Journal:  Am J Med       Date:  1989-11-30       Impact factor: 4.965

View more
  14 in total

1.  Predicting effect of food on extent of drug absorption based on physicochemical properties.

Authors:  Chong-Hui Gu; Hua Li; Jaquan Levons; Kimberley Lentz; Rajesh B Gandhi; Krishnaswamy Raghavan; Ronald L Smith
Journal:  Pharm Res       Date:  2007-03-24       Impact factor: 4.200

2.  Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing.

Authors:  Michael Derks; Markus Abt; Anne Mwangi; Georgina Meneses-Lorente
Journal:  Eur J Clin Pharmacol       Date:  2010-06-03       Impact factor: 2.953

Review 3.  A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.

Authors:  Anushka Naidoo; Kogieleum Naidoo; Helen McIlleron; Sabiha Essack; Nesri Padayatchi
Journal:  J Clin Pharmacol       Date:  2017-07-24       Impact factor: 3.126

Review 4.  Moxifloxacin in uncomplicated skin and skin structure infections.

Authors:  Richard B R Muijsers; Blair Jarvis
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Thorough QT study of the effect of oral moxifloxacin on QTc interval in the fed and fasted state in healthy Japanese and Caucasian subjects.

Authors:  Jorg Taubel; Georg Ferber; Ulrike Lorch; Velislav Batchvarov; Irina Savelieva; A John Camm
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

Review 6.  Moxifloxacin: a review of its use in the management of bacterial infections.

Authors:  Gillian M Keating; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis.

Authors:  Chiu-Yeung Chan; Carrie Au-Yeang; Wing-Wai Yew; Chi-Chiu Leung; Augustine F B Cheng
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

8.  Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children.

Authors:  Kendra K Radtke; Anneke C Hesseling; J L Winckler; Heather R Draper; Belen P Solans; Stephanie Thee; Lubbe Wiesner; Louvina E van der Laan; Barend Fourie; James Nielsen; H Simon Schaaf; Radojka M Savic; Anthony J Garcia-Prats
Journal:  Clin Infect Dis       Date:  2022-04-28       Impact factor: 20.999

9.  Moxifloxacin in the treatment of skin and skin structure infections.

Authors:  David Rp Guay
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

10.  Tafenoquine at therapeutic concentrations does not prolong Fridericia-corrected QT interval in healthy subjects.

Authors:  Justin A Green; Apurva K Patel; Bela R Patel; Azra Hussaini; Emma J Harrell; Mirna J McDonald; Nick Carter; Khadeeja Mohamed; Stephan Duparc; Ann K Miller
Journal:  J Clin Pharmacol       Date:  2014-04-09       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.